MarketCap
Vertex Pharmaceuticals Incorporated VRTX
Facebook
X
Telegram
Country |
 USA |
IPO year |
1991 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
256 M |
Market Cap[1] |
$ 140 B |
EBITDA (LTM) |
$ 2.77 B |
P/E (LTM) |
63.19 |
P/S (LTM) |
19.04 |
EPS (LTM) |
8.4 |
Vertex Pharmaceuticals is an American biotechnology company specializing in the development of drugs for the treatment of rare diseases. The company was founded in 1989 in Cambridge, Massachusetts.
Vertex Pharmaceuticals' main area of focus is the research and development of new drugs for the treatment of genetic diseases such as cystic fibrosis, Berger's syndrome, thalassemia, and others.
One of the company's most well-known products is the drug Kalydeco, which is used to treat cystic fibrosis. In addition, Vertex Pharmaceuticals is working on the development of new drugs for the treatment of cancer, Parkinson's disease, and other conditions.
The company actively invests in scientific research and the development of new drugs. Vertex Pharmaceuticals collaborates with universities, research centers, and other companies to expand its scientific potential and improve its products.
Vertex Pharmaceuticals has a wide network of distributors and partners around the world, which allows it to provide its products to patients in various countries. The company strives for continuous improvement of its products and expansion of its activities to meet the needs of patients worldwide.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Celsion Corporation
CLSN
|
- | -6.63 % | $ 13.9 M | Nasdaq Capital Market | USA |
 |
FSD Pharma
HUGE
|
- | 5743.5 % | $ 69.7 M | Nasdaq Capital Market |  Canada |
 |
Synthetic Biologics
SYN
|
- | 1.32 % | $ 16.2 M | NYSE American | USA |
 |
Dynavax Technologies Corporation
DVAX
|
- | - | $ 2.02 B | Nasdaq Capital Market | USA |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market |  China |
 |
Corner Growth Acquisition Corp.
COOL
|
- | -0.89 % | $ 114 M | Nasdaq Global Select Market | USA |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Qilian International Holding Group Limited
QLI
|
- | -6.08 % | $ 184 M | Nasdaq Global Select Market | China |
 |
Happiness Biotech Group Limited
HAPP
|
- | 1.35 % | $ 17.8 M | Nasdaq Capital Market | China |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market |  France |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | France |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market |  Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Athira Pharma
ATHA
|
- | - | $ 269 M | Nasdaq Global Select Market | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
- | 0.74 % | $ 768 M | Nasdaq Capital Market |  Israel |
 |
Abcam plc
ABCM
|
- | - | $ 4.9 B | Nasdaq Global Select Market |  Britain |
 |
Завод ДИОД
DIOD
|
- | - | - | MOEX,SPB |  Russia |
|
Galera Therapeutics
GRTX
|
- | -32.59 % | $ 7.61 M | Nasdaq Global Market | USA |
 |
Генетико
GECO
|
- | - | - | MOEX | Russia |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | Britain |
 |
Hepion Pharmaceuticals
HEPA
|
- | -18.79 % | $ 39.3 K | Nasdaq Capital Market | USA |
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market | Germany |
 |
Codexis
CDXS
|
$ 1.46 | 2.82 % | $ 127 M | Nasdaq Global Select Market | USA |
 |
Ardelyx
ARDX
|
$ 3.78 | 1.89 % | $ 911 M | Nasdaq Global Market | USA |
 |
Affimed N.V.
AFMD
|
- | -34.95 % | $ 21.5 M | Nasdaq Global Select Market,SPB | Germany |
 |
ОЗОН Фармацевтика
OZPH
|
- | - | - | MOEX | Russia |
 |
Arcutis Biotherapeutics
ARQT
|
$ 23.9 | 1.01 % | $ 3.04 B | Nasdaq Global Select Market,SPB | USA |
 |
Assembly Biosciences
ASMB
|
$ 36.6 | 1.3 % | $ 410 M | Nasdaq Global Select Market,SPB | USA |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
- | -1.58 % | $ 28.1 M | Nasdaq Global Market | China |
 |
Celyad Oncology SA
CYAD
|
- | - | $ 12.5 M | Nasdaq Global Market |  Belgium |
 |
Adial Pharmaceuticals
ADIL
|
$ 7.12 | 6.91 % | $ 4.76 M | Nasdaq Capital Market | USA |
 |
Generation Bio Co.
GBIO
|
- | - | $ 344 M | Nasdaq Global Select Market | USA |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
- | -4.36 % | $ 27 M | Nasdaq Capital Market | USA |
 |
Gracell Biotechnologies
GRCL
|
- | - | $ 3.37 B | Nasdaq Global Select Market | China |
 |
Axsome Therapeutics
AXSM
|
$ 206.68 | 0.16 % | $ 10.3 B | Nasdaq Global Market,SPB | USA |
 |
GlycoMimetics
GLYC
|
- | 9357.83 % | $ 1.01 B | Nasdaq Global Market | USA |
 |
AnaptysBio
ANAB
|
$ 56.8 | 0.94 % | $ 1.63 B | Nasdaq Global Select Market,SPB | USA |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | Canada |
 |
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | USA |
 |
BioMarin Pharmaceutical
BMRN
|
$ 66.53 | 0.15 % | $ 12.8 B | Nasdaq Global Select Market,SPB | USA |
 |
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market |  Cayman-islands |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | Canada |
 |
Bicycle Therapeutics plc
BCYC
|
$ 4.3 | 1.42 % | $ 298 M | Nasdaq Global Select Market | Britain |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
ChromaDex Corporation
CDXC
|
- | -0.88 % | $ 598 M | Nasdaq Capital Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.